8-K: BioAtla Licenses Bispecific Antibody Assets to Context Therapeutics in Deal Worth up to $133.5 Million

BioAtla has granted Context Therapeutics an exclusive worldwide license to develop and commercialize two bispecific antibodies, including BA3362, for a potential total of $133.5 million plus royalties.

Summary

• BioAtla has entered into a license agreement with Context Therapeutics, granting Context exclusive worldwide rights to develop, manufacture, and commercialize two licensed antibodies, including BA3362, which Context has renamed CT-202.
• The agreement includes a potential $133.5 million in payments to BioAtla, consisting of $15 million in upfront and near-term milestones, and $118.5 million in additional milestone payments based on pre-clinical, clinical, development, and commercial achievements.
• BioAtla will also receive tiered mid-single digit to low double-digit royalties on future net sales of products containing the licensed assets.
• BioAtla has agreed to refrain from certain competitive activities related to bispecific or multi-specific antibodies targeting Nectin-4.
• The license agreement continues on a country-by-country, product-by-product basis until the expiration of the royalty term, unless terminated earlier.
• The agreement can be terminated by either party for material breach or insolvency, by Context at will with advance notice, or by BioAtla if Context fails to conduct research or development for eight consecutive quarters.
• BioAtla also entered into a Global Transaction Agreement with Himalaya Therapeutics, where Himalaya consented to the license agreement and granted BioAtla an exclusive, worldwide, sublicensable license to related patents and know-how.
• BioAtla will pay Himalaya a mid-teens percentage of upfront and development milestone payments received from Context, and a specified percentage of sales milestones and royalties from net sales in China, Hong Kong, Macao, and Taiwan.

Sentiment

Score: 7

Explanation: The document is positive overall, as it represents a significant licensing deal for BioAtla, providing potential future revenue and validation of their technology. However, the deal also includes some risks and limitations, such as the competitive restriction and the dependence on Context's success.

Positives

• BioAtla secures a significant potential revenue stream through milestone payments and royalties.
• The deal validates BioAtla's bispecific antibody technology.
• Context Therapeutics will take on the development and commercialization costs and risks.
• BioAtla retains a portion of the upside through royalties.
• The agreement includes an exclusive license, which provides a clear path for Context to develop and commercialize the assets.

Negatives

• BioAtla is restricted from competing in the development of bispecific or multi-specific antibodies directed against Nectin-4.
• The majority of the potential revenue is contingent on future milestones, which may not be achieved.
• BioAtla will share a portion of the revenue with Himalaya Therapeutics.

Risks

• The success of the licensed antibodies is dependent on Context's ability to successfully develop and commercialize them.
• Clinical trials may not be successful, and regulatory approvals may not be granted.
• The market for these therapies may not be as large as anticipated.
• Competition from other companies developing similar therapies could impact sales.
• The agreement could be terminated if Context fails to meet certain development milestones or breaches the agreement.

Future Outlook

The agreement positions BioAtla to potentially receive significant revenue through milestone payments and royalties as Context Therapeutics advances the development and commercialization of the licensed antibodies. The success of this partnership will depend on the clinical and commercial performance of the licensed assets.

Industry Context

This agreement reflects the ongoing trend of pharmaceutical companies licensing promising drug candidates to accelerate their development and commercialization. Bispecific antibodies are a growing area of interest in the pharmaceutical industry, and this deal highlights the value of BioAtla's technology in this space.

Comparison to Industry Standards

• The upfront payment of $11 million is within the typical range for early-stage licensing deals in the biotech industry, but the total potential value of $133.5 million plus royalties is significant, indicating the perceived potential of the licensed assets.
• Comparable deals in the bispecific antibody space often include similar structures with upfront payments, milestone payments tied to clinical and regulatory progress, and tiered royalties on net sales.
• For example, a similar deal might include an upfront payment of $5-20 million, development milestones of $50-150 million, and sales milestones of $100-300 million, with royalties ranging from mid-single digits to low double digits.
• The specific terms of this deal, such as the royalty rates and the specific milestones, are not fully disclosed, making a precise comparison difficult, but the overall structure is consistent with industry norms.

Related Party Transactions

• The Global Transaction Agreement with Himalaya Therapeutics is a related party transaction, as Himalaya was previously granted rights to the assets in certain territories.

Stakeholder Impact

• Shareholders of BioAtla will benefit from the potential revenue stream and validation of the company's technology.
• Context Therapeutics will gain access to promising drug candidates to expand their pipeline.
• Himalaya Therapeutics will receive a portion of the payments from Context.
• Patients may benefit from the development of new therapies for cancer.

Next Steps

• Context Therapeutics will begin development and commercialization activities for the licensed antibodies.
• BioAtla will transfer relevant intellectual property and materials to Context.
• The companies will form a Patent Committee to discuss patent-related matters.
• Context will be responsible for all regulatory submissions and approvals.
• BioAtla will monitor Context's progress and provide support as needed.

Key Dates

Keywords

bispecific antibody, license agreement, Context Therapeutics, BioAtla, BA3362, CT-202, Nectin-4, CD3, milestone payments, royalties, Himalaya Therapeutics, intellectual property